Biotech Values

[DewDiligence]

(PFE)—LLY’s oral GLP-1 data come_up_a_bit_short:

https://www.evaluate.com/vantage/articles/events/conferences/ada-2023-preview-lillys-oral-obesity-data-leave-room-pfizer

New data, which were apparently released accidentally yesterday, gave investors the first look at ]LLY’s] oral GLP-1 contender orforglipron, which is in phase 3 development.

…Mid-stage data revealed in an American Diabetes Association abstract showed 12.6% weight loss with the oral at 26 weeks – lower than the 14-15% Lilly had previously estimated. At the same time point, Mounjaro had produced weight loss of around 15%.

…The results could leave the door open for a new entrant, Pfizer, which is expected to unveil phase 2 obesity data on two oral GLP-1s, danuglipron and lotiglipron (PF-07081532), this year.

Please see #msg-171964881 for related info.